Skip to main
HOWL

Werewolf Therapeutics (HOWL) Stock Forecast & Price Target

Werewolf Therapeutics (HOWL) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Werewolf Therapeutics Inc. is expected to benefit from the positive financial metrics associated with its innovative therapeutics development, highlighted by the company's use of the PREDATOR platform to enhance immune system responses against cancer. The increase in Core Funds From Operations (FFO) guidance to a range of $1.84-$1.88 reflects a significant year-over-year growth of 5.1%, indicating strong operational performance. Additionally, the achieved same-store net operating income (NOI) expansion of 4.1%, alongside a 4.3% growth in blended rent, demonstrates robust demand drivers that may translate favorably for investor sentiment in the biopharmaceutical sector.

Bears say

The analysis indicates a negative outlook for Werewolf Therapeutics due to weakening revenue growth projections, as full-year same-store revenue growth has been revised downward from a range of (0.35%)-1.15% to a new range of (0.20%)-0.40%. Additionally, the decline in the average effective rental rate, coupled with an increase in expenses of 3.8% year-over-year, has resulted in a 2.6% decline in net operating income (NOI). This financial strain is compounded by new lease rate growth underperforming relative to expectations, suggesting potential challenges in revenue generation moving forward.

Werewolf Therapeutics (HOWL) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Werewolf Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Werewolf Therapeutics (HOWL) Forecast

Analysts have given Werewolf Therapeutics (HOWL) a Buy based on their latest research and market trends.

According to 4 analysts, Werewolf Therapeutics (HOWL) has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Werewolf Therapeutics (HOWL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.